BioTuesdays
Viking Therapeutics Logo

Viking, Kennedy Krieger to collaborate in X-ALD

Viking Therapeutics (NASDAQ:VKTX) and the Kennedy Krieger Institute announced a sponsored research collaboration focused on evaluating Viking’s thyroid beta agonists for the treatment of X-linked adrenoleukodystrophy (X...

Viking Therapeutics Logo

Viking submits IND for Phase 2 trial of VK2809

Viking Therapeutics (NASDAQ:VKTX) has submitted an IND application to the FDA to conduct a Phase 2 study of VK2809 in patients with hypercholesterolemia and fatty liver disease. Viking expects to initiate the Phase 2...

Dipexium Pharmaceuticals

Dipexium Phase 3 Locilex trials 62% enrolled

Dipexium Pharmaceuticals’ (NASDAQ:DPRX) OneStep Phase 3 placebo-controlled, pivotal clinical trials of Locilex in the treatment of patients with mild infections of diabetic foot ulcers are approximately 62% enrolled...

Avivagen

Avivagen, COFCO to conduct OxC-beta trial on pigs

Avivagen (TSX-V:VIV) and COFCO Nutrition and Health Research Institute (NHRI), an affiliate of the Chinese government’s COFCO Group, have agreed to conduct a trial of OxC-beta Livestock as a feed additive for swine. The...

Avivagen

Avivagen in credit facility with Bloom Burton

Avivagen (TSX-V:VIV) has signed an agreement with the Bloom Burton Healthcare Lending Trust for a secured drawdown credit facility of up to $1.8-million. The facility will advance Avivagen’s plans for commercializing...

Transition Therapeutics

Transition Therapeutics sets Phase 2 SARM trial

Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has entered an agreement for an investigator-led clinical study of drug candidate, TT701, with Brigham and Women’s Hospital (BWH). Transition will support the Phase 2 study...

novadaq

Novadaq Q3 revenue climbs 40%

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) reported revenue of $17-million for the third quarter this year, an increase of 40% from $12.1-million a year ago. Product sales increased by $5.2-million, or 47%, primarily...

Avivagen

Avivagen sets OxC-beta swine trial in Vietnam

Avivagen (TSX-V:VIV) has agreed with the National Institute of Animal Sciences for Vietnam (NIAS) to conduct a further trial of OxC-beta livestock as a feed additive for swine. Earlier this year, Avivagen and NIAS...

Titan Pharmaceuticals Logo

Obama to expand MAT in opioid addiction

President Barack Obama has tackled the opioid epidemic this week by telling health care providers across the country that access to medication-assisted treatment (MAT) must be expanded. He released an order giving...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.